ArticleDrug safety2026
Sexual Dysfunction Among Males Living with HIV Receiving Dolutegravir-Based Antiretroviral Therapy in Uganda: A Cross-sectional Study.
Article in Drug safety, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundDolutegravir, the anchor drug of combination antiretroviral therapy (cART), has been associated with sexual dysfunction. We have evaluated the burden, correlates and nature of sexual dysfunction among Ugandan males living with HIV receiving dolutegravir-based antiretroviral therapy.
methodsIn a cross-sectional study in one health centre, we collected sociodemographic and clinical data via structured interviews, undertook clinical examinations and performed data abstraction from electronic medical records. Sexual function was evaluated using the International Index of Erectile Function and the Changes in Sexual Functioning Questionnaire. Modified Poisson regression was utilised to estimate prevalence ratios (PRs), modelling dolutegravir exposure as the primary independent variable while adjusting for sociodemographic and clinical factors as secondary covariates.
resultsThe prevalence of erectile dysfunction among males receiving dolutegravir-based cART for > 1 day to 6 months was twice that of cART-naive males (59% vs 26%) and plateaued thereafter. Dolutegravir exposure was associated with erectile dysfunction with adjusted PRs > 2 at all timepoints (> 1 day to > 2 years) compared with cART-naïve males. Older age, living with a partner, self-reported adherence, and moderate-to-severe depression were also associated with sexual dysfunction. Sexual desire frequency dysfunction was associated with dolutegravir exposure among males receiving dolutegravir for > 1 day to 6 months (PR 1.15, 95% CI 1.05-1.26) versus > 2 years.
conclusionsDolutegravir is associated with transient central sexual desire suppression and persistent peripheral erectile dysfunction. This has the potential to lead to non-adherence and virological rebound, which needs to be monitored to safeguard the long-term success of cART.
Identifiers
42440201What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.